Login
Xtant Medical Holdings, Inc. logo

Xtant Medical Holdings, Inc.

xtantmedical.com

What Do They Do?

Develops and sells bone graft materials and spinal implant systems used by orthopedic spine surgeons, neurosurgeons and other orthopedic and wound-care specialists.

How Do They Make Money?

The company sells biologics and spinal products to hospitals when used in surgery, and invoices resellers when products ship or are delivered. License agreements bring upfront fees and royalties based on product sales.

revenue
SegmentShareRevenue
Orthobiologics
Sold outright

54%
FY2022: 81%
Spinal Implant
Sold outright

32%
FY2022: 19%
License Revenue
Licensed

14%

Who Are Their Customers?

U.S. hospitals are served through commissioned agents and stocking distributors, with agents accessing hospital networks and purchasing groups. The company also sells to domestic and international resellers and serves international markets through distribution partners.

Do Revenues Turn Into Profits?

Yes. It kept 4 cents of every revenue dollar as net income in FY2025 and turned 8 cents into free cash flow.

Operating income, FY2025
5% of revenue
▲ Turned profitable vs FY2024 (−$12.1M, −10%)
Net income, FY2025
4% of revenue
▲ Turned profitable vs FY2024 (−$16.4M, −14%)
Free cash flow, FY2025
8% of revenue
▲ Turned profitable vs FY2024 (−$16M, −14%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −27%
vs $33.3M in Q3 FY2025
Net income
▼ Turned to a loss
vs $1.3M in Q3 FY2025
Orthobiologics share of revenue vs 51.6% in Q3 FY2025
  • Aug 11, 2026 Reduced full-year revenue guidance Lowered the full-year range to $99 million to $103 million from $101 million to $105 million.
  • May 13, 2026 Raised 2026 revenue guidance after adding HEMOBLAST Raised the range to $101 million to $105 million from $95 million to $99 million, reflecting expected HEMOBLAST sales.
  • Apr 10, 2026 Secured exclusive U.S. rights to distribute HEMOBLAST Xtant also hired approximately 20 Dilon sales personnel to sell the product in the United States.

Growing. Revenue grew 2.4x in 4 years, from $55.3M in FY2021 to $133.9M in FY2025, about 25% a year.

Broader biologics applications The older overview centered on spinal procedures; the latest also describes biologics for trauma, foot and ankle, sports medicine, joint replacement, surgical repair and wound care.

Exited international hardware operations The older report described international product sales through partners; the latest says Xtant sold its international hardware business while continuing to serve international markets through distribution partners.

Revenue over time
Orthobiologics Spinal Implant License Revenue Other Revenue
$200M$100M$0

Who Do They Compete With?

Competes with Medtronic, Johnson and Johnson, Bioventus, Globus Medical, OrthoFix Medical, Alphatec Holdings, Highridge, SI-Bone, AlloSource International, LifeNet Health, and MTF Biologics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support